Details for Patent: 10,610,502
✉ Email this page to a colleague
Which drugs does patent 10,610,502 protect, and when does it expire?
Patent 10,610,502 protects OZOBAX and is included in one NDA.
Summary for Patent: 10,610,502
| Title: | Oral baclofen solutions |
| Abstract: | The present disclosure relates to aqueous oral solutions comprising baclofen. In one embodiment, the aqueous oral solutions comprise a buffer comprising citric acid, a salt of citric acid, or any combination thereof, and are stored at from about 2.degree. C. to about 8.degree. C. The present disclosure also relates to buffer free aqueous oral solutions comprising baclofen. Additionally, the present disclosure relates to an assay for determining the amount of an impurity, 4-(3-carboxymethyl)-3-hydroxy-2,5-dioxopyrrolidin-1-yl)-3-(4-chlorophenyl- )butanoic acid, in a baclofen containing solution, and to methods of treatment using such aqueous oral solutions. |
| Inventor(s): | Bryant; Thomas Jeffrey (Athens, GA), Thomas; H. Greg (Athens, GA) |
| Assignee: | Metacel Pharmaceuticals, LLC (Athens, GA) |
| Application Number: | 16/556,893 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 10,610,502
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metacel Pharms Llc | OZOBAX | baclofen | SOLUTION;ORAL | 208193-001 | Sep 18, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SPASTICITY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
